Nina Capital has announced the first close of its €50 million Fund III, which will focus on early-stage investments in the health technology sector. The fund has secured contributions from various investors, including Boston-based wealth management firm Seven Two Partners, professional family offices, foundations, corporations, and individuals across Europe and the United States. With this new funding, the firm aims to expand its investment reach into additional regions and support emerging healthtech startups.
Nina Capital has previously invested in multiple health-focused startups, primarily in Europe and North America. This latest fund marks an expansion into new territories, including Israel and Australia. The firm’s earlier funds targeted similar stages of investment, ranging from pre-seed to Series A, to support startups addressing key challenges in healthcare. By broadening its geographical reach, Nina Capital aims to identify new opportunities in the evolving healthtech landscape.
What is Nina Capital’s strategy with Fund III?
Fund III will continue the firm’s approach of investing in startups from pre-seed to Series A stages. Initial investment amounts will range between €250,000 and €1.5 million, with additional reserves allocated for follow-on funding. The goal is to support companies working on technological advancements that enhance healthcare delivery and patient outcomes. The fund’s expansion into Australia marks a significant step in diversifying its portfolio.
Which company has received the first investment?
The first company to receive funding from Fund III is Sonar Mental Health, a U.S.-based platform that integrates AI and human-led support to assist students with mental health challenges. Nina Capital plans to make two additional investments in early 2025, continuing its focus on companies that leverage technology to address healthcare issues.
Andrew Macken, Managing Partner at Seven Two Partners, expressed optimism about Nina Capital’s approach, stating:
“Healthcare is at the forefront of a transformative era, where groundbreaking innovations are creating immense opportunities for both patient impact and investors.”
He emphasized the importance of supporting strong founders in tackling complex healthcare problems and highlighted Nina Capital’s role in fostering these innovations.
This new fund reflects an ongoing trend of increased venture capital investment in digital health and medical technology startups. Investors are seeking opportunities in companies that utilize AI, data analytics, and new medical technologies to improve patient care. By expanding its investment strategy geographically, Nina Capital positions itself to discover innovative solutions in various healthcare markets.
As healthtech continues to evolve, funding initiatives such as Fund III play a role in advancing medical innovations. Startups receiving early-stage investments often contribute to the development of new healthcare models, integrating AI, data-driven diagnostics, and digital platforms. For entrepreneurs in this sector, securing capital from specialized funds like Nina Capital provides opportunities to expand operations and refine their technologies. The firm’s focus on multiple regions may also help address healthcare challenges on a broader scale, supporting businesses that create impactful solutions.
